BUSINESS NAME

NEWSLETTER T ITLE Diseases | Surgery of the Retina and Vitreous

WELCOMING JEFFREY J. TAN , MD

Jeffrey J. Tan, MD graduated with a bachelor’s degree in business administration from the Haas School of Business at University of California, Berkeley, California. Dr. Tan then went on to earn his medical degree at Boston University School of Medicine, Boston, Massachusetts. He completed his ophthalmology residency at SUNY Downstate Medical Center in Brooklyn, NY, where he served as chief resident and received the Kings County resident of the year award and the Richard C. Troutman award for academic excellence. During his training there, he was also awarded the Association of University Professors of Ophthalmology (AUPO) research award and the SUNY Downstate research award. He has subsequently completed a two-year fellow-ship in vitreo-retinal diseases and surgery at the USC Roski Eye Institute, Los Angeles, Califor-nia. He has been awarded the prestigious Vit-Buckle Society Best Fellow Surgical Award two years in a row. Dr. Tan has published in multiple journals and book chapters, and has developed a novel surgical technique to improve visualization during pars plana vitrectomy. Dr. Tan is fluent in Mandarin and speaks medical Spanish.

Dr. Tan is getting married next May and enjoys spending time with his fiancé and 2 dogs. Dr. Tan is accepting new patients at our Los Angeles, Pasadena, Torrance, Beverly Hills, and North Hollywood locations.

OCT-ANGIOGRAPHY TESTING

Optical coherence tomography angiography (OCT-A) is a new non-invasive imaging modali-ty that can capture high-resolution blood flow without the need of needles and intravenous dye injection. It employs ultra high-speed scanning to provide detailed three-dimensional reconstruction of the blood vessels of the retina and choroid in a matter of seconds. This helps assess disorders such as age-related macular degeneration, choroidal neovasculariza-tion, retinal vascular occlusion, diabetic retinopathy, central serous chorioretinopathy, my-opic degeneration, and more. Although OCT-A has its advantages, it cannot yet replace traditional approaches such as fluorescein angiography (FA) and indocyanine green (ICG) due to certain limitations.

Please visit our NEW website for updates, doctor profiles, new clinical trials, and more!

www.LAretina.com

NEW WEBSITE

CURRENTLY ENROLLING CLINICAL TRIALS

Transportation may be provided. Informed consents may be available in English, Spanish, Russian, Armenian, Chinese, Korean

Retina-Vitreous Associates Medical Group has participated in clinical research for over 15 years and is committed to the development of novel diagnostic and therapeutic modalities for retinal disease. All of our physicians participate in clinical trials, giving patients unique and easy access to the latest developments in treatments of vitreoretinal diseases. We are com-mitted to bettering the quality, efficacy and ease of treatment for our patients.

We are currently enrolling patients for the conditions below and are actively engaging in new trials.

RETINITIS PIGMENTOSA (RP)

A genetic condition causing progressive vision loss. Night blindness usually occurs first, followed by peripheral, central, and color vision loss.

We offer injections of human stem cell-derived retinal progenitor cells in the office that may offer long-term visual benefits to pa-tients who otherwise have no other treatments available.

MACULAR DEGENERATION (Age-related/AMD)

The leading cause of vision loss in America, AMD is progressive disorder affecting the central vision in patients 50 years or older.

“Dry” macular degeneration: currently no treatment available.

“Wet” macular degeneration: current standard of care treatment includes frequent eye injections

We provide trials for both early and end stage dry and wet AMD using in-office as well as surgical treatments.

DIABETIC RETINOPATHY

Patients with type 1 and type 2 diabetes can suffer from damage to the blood vessels in the retina, causing mild to severe vision loss and potentially blindness.

Currently under investigation are an orally administered pill and a subcutaneous (underneath the skin) self-administered injection.

DIABETIC MACULAR EDEMA (DME)

An accumulation of swelling in the central retina that causes vision loss in diabetic patients. This is a component of diabetic retinopa-thy.

Our trials look for novel treatments for diabetic macular edema and in combination with current gold-standard treatment.

RETINAL VEIN OCCLUSION (CRVO and BRVO)

Commonly referred to as a “stroke in the eye”, a blood clot in the retinal blood vessels can cause vision loss and secondary glaucoma.

We are investigating multiple novel treatments to improve outcomes and decrease the number of necessary visits and procedures.

UVEITIS: ANTERIOR, INTERMEDIATE, POSTERIOR, AND PAN-UVEITIS

A broad term for inflammation of the eye, it can be classified based on the parts of the eye that are affected.

We offer a spectrum of treatments including eye drops, subcutaneous injections, and oral medication for various types of uveitis.

STUDY RESULTS UPDATES

RVA 2017 PUBLICATIONS

1. Shields CL, Roe R, Yannuzzi LA, Shields JA. SOLITARY CIRCUMSCRIBED "PEARL WHITE" RETINAL MASS (SO-CALLED RETINAL ASTROCYTIC PROLIFERATION) RESIDES IN DEEP RETINA OR BENEATH RETINA: FINDINGS ON MULTIMODAL IMAGING IN 4 CASES. Retin Cases Brief Rep. 2017 Winter;11(1):18-23.

2. Esmaili DD. IATROGENIC OCCLUSION OF THE OPHTHALMIC ARTERY AFTER SODIUM TETRADECYL SULFATE INJECTION IN THE FORE-HEAD. Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S28-S30.

3. Borrelli E, Abdelfattah NS, Uji A, Nittala MG, Boyer DS, Sadda SR. Postreceptor Neuronal Loss in Intermediate Age-related Macular Degeneration. Am J Ophthalmol. 2017 Sep;181:1-11.

4. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, Do DV, Nguyen QD. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Non-Infectious Uveitis. Am J Ophthalmol. 2017 Sep 5.

5. Hahn P, Schneider EW, Tabandeh H, Wong RW, Emerson GG; American Society of Retina Specialists Research and Safety in Therapeutics (ASRS ReST) Committee. Reported Complications Following Laser Vitreolysis. JAMA Ophthalmol. 2017 Sep 1;135(9):973-976.

6. Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik JF, Stemper B, Asmus F, Rittenhouse KD, Ahlers C, Vitti R, Saroj N, Zeitz O, Haller JA. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017 Aug 23;11:1533-1540.

7. Tan JJ, Cai CL, Shrier EM, McNally L, Lazzaro DR, Aranda JV, Beharry KD. Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Inter-mittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy. J Ophthalmol. 2017:4353129.

8. Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017 Aug 17;2(16).

9. Wykoff CC, Ou WC, Khurana RN, Brown DM, Lloyd Clark W, Boyer DS; ENDURANCE Study Group. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2017 Aug 16.

10. Jackson TL, Boyer D, Brown DM, Chaudhry N, Elman M, Liang C, O'Shaughnessy D, Parsons EC, Patel S, Slakter JS, Rosenfeld PJ. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study. JAMA Ophthalmol. 2017 Jul 1;135(7):761-767.

11. Tabandeh H. A Surgical Technique for the Management of Retinal Detachment Associated With Severe Proliferative Vitreoretinopathy. Retina. 2017 Jul;37(7):1407-1410.

12. Valencia AM, Cai CL, Tan J, Duggan TJ, Valencia GB, Arand JV, Beharry KD. Intravitreal bevacizumab alters type IV collagenases and exacerbates arrested alveologenesis in the neonatal rat lungs. Exp Lung Res. 2017 Apr;43(3):120-133.

13. Uji A, Abdelfattah NS, Boyer DS, Balasubramanian S, Lei J, Sadda SR. Variability of Retinal Thickness Measurements in Tilted or Stretched Optical Coher-ence Tomography Images. Transl Vis Sci Technol. 2017 Mar 1;6(2):1.

14. Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmol. 2017 Mar 1;135(3):268-273.

15. Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SEC-ONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina. 2017 May;37(5):819-835.

16. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 Jan;124(1):74-81.

Apellis– Geographic Atrophy

- The Filly study enrolled 246 pa-tients and involved the intravitreal injection of APL-2, a complement C3 inhibitor

- After 12 months, monthly APL-2 showed a 29% reduction in the rate of GA growth vs placebo

- Every other month treatment showed 20% reduction

- Following these positive results, phase III will begin enrollment 2018

Genentech– Geographic Atrophy

- Lampalizumab, a monoclonal anti-body targeting complement system, investigated in phase III trials:

- Spectri: treatment on hold after ana-lyzing results

- Chroma: results expected end of 2017

- Following the results of the Chroma study, Genentech will make a decision on future Lampalizumab administra-tion

Cell Cure– Geographic Atrophy

- OpRegen Study of Stem Cell-Derived RPE Cells

- Preclinical studies have shown that after a single subretinal injection, cells have the potential to support and replace the degeneration of the retinal pigment epithelium

- Evidence that injected cells may be found in subretinal space in animals

- Retina-Vitreous Associates is cur-rently enrolling for the surgical study

CONTACT INFORMATION

Main Phone: (213) 483-8810 Clinical Trials Center: (310) 289-2478 x3

www.LAretina.com Clinical Trials Fax: (310) 652-1956

Beverly Hills 9001 Wilshire Blvd., Suite 301 Beverly Hills, CA 90211 Phone: (310) 854-6201 FAX: (310) 652-7520

Los Angeles 1245 Wilshire Blvd., Suite 380 Los Angeles, CA 90017 Phone: (213) 483-8810 FAX: (213) 481-1503

North Hollywood 12840 Riverside Drive, Suite 333 North Hollywood, CA 91607 Phone: (818) 754-2090 FAX: (818) 508-9420

Pasadena 301 S. Fair Oaks Ave, Suite 407 Pasadena, CA 91105 Phone: (626) 204-1410 Fax: (626) 204-1420

Tarzana 5525 Etiwanda Ave. Suite 112 Tarzana, CA 91356 Phone: (818) 578-7408 FAX: (818) 578-7409

Torrance 3400 Lomita Blvd., Suite 202 Torrance, CA 90505 Phone: (310) 891-1000 FAX: (310) 891-1003

Daniel D. Esmaili, MD Alexander C. Walsh, MD Jeffrey J. Tan, MD David S. Liao, MD Richard H. Roe, MD Pouya N. Dayani, MD

David S. Boyer, MD Roger L. Novack, MD Thomas G. Chu, MD Firas M. Rahhal, MD Homayoun Tabandeh, MD

RVA 2017 PRESENTATIONS AND AWARDS

1. Rahhal, Firas M. "Seed Stage Financing", Ophthalmic Innovation Summit at the American Society of Retina Specialists Annual Meeting. Boston, MA, August, 2017.

2. Boyer, David S. Alumnus of the Year Award 2017. USC Roski Eye Institute. 3. Tan, Jeffrey J. “Visual Outcome with Immunomodulatory Intervention in Chronic Vogt-Koyanagi-Harada Disease.” Scientific Presentation. ARVO. May 7,

2017. Baltimore, MD. 4. Tan, Jeffrey J. “Complement Inhibition in Age-Related Macular Degeneration.” Invited Speaker. Global Ocular Inflammation Workshop. April 27, 2017.

Bali, Indonesia. 5. Tan, Jeffrey J. “Factors Contributing to Chronic Vogt-Koyanagi-Harada Development.” Invited Speaker. Global Ocular Inflammation Workshop. April 27,

2017. Bali, Indonesia. 6. Tan, Jeffrey J. Vit-Buckle Society Best Fellow Surgical Video/CONNECT Network Grant Winner April 2017 7. Rahhal, Firas M. Panelist, "Funding Innovation: Venture Capital Panel Discussion", Glaucoma 360 Annual Meeting. San Francisco, CA, February, 2017.